[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shahid Beheshti University of Medical Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":390},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,42,75,98,119,141,162,181,199,229,250,270,301,320,346,367],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100602413","oregano-and-basil-leaves-and-coronary-artery-disease-100602413",false,"NCT07123181","Oregano and Basil Leaves and Coronary Artery Disease","Effects of Increasing Polyphenol Intake by Consumption of Oregano and Basil Leaves on Plasma Inflammatory and Lipid Factors and Total Urinary Polyphenol in Patients With Unstable Angina","Inclusion Criteria:\n\n* Patients diagnosed with unstable angina\n\nExclusion Criteria:\n\n* Patients diagnosed with STEMI\n* Patients undergoing coronary artery bypass grafting\n* Liver cirrhosis and advanced chronic kidney disease (CKD 5)\n* Having known inflammatory and autoimmune diseases, such as inflammatory bowel disease (IBD) and rheumatoid arthritis, or taking glucocorticoid medications\n* Pregnancy or breastfeeding","ALL","30 Years","75 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","The present study will examine the effects of increasing dietary polyphenol intake by consumption of oregano and basil leaves, on plasma inflammatory and lipid factors and total urinary polyphenol levels in patients who have recently had unstable angina.",[27,28],"Acute Coronary Syndromes","Unstable Angina (UA)","RECRUITING","2026-06-13",{"date":32,"type":33},"2026-06-16","ACTUAL",{"date":35,"type":33},"2025-09-01",{"date":37,"type":21},"2026-10-22",{"name":39,"class":40},"Shahid Beheshti University of Medical Sciences","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":41},"100635413","chatgpt-driven-blended-teaching-for-pain-management-in-nursing-students-a-randomized-controlled-trial-100635413","NCT07552363","ChatGPT-Driven Blended Teaching for Pain Management in Nursing Students: A Randomized Controlled Trial","Effect of a ChatGPT-Driven Blended Teaching Model for Pain Management on Knowledge, Attitudes, Competence, and Self-Efficacy Among Nursing Students: A Two-Arm Parallel-Group Randomized Controlled Trial","Inclusion Criteria:\n\n1. Undergraduate nursing students in their fourth semester or higher, or master's or doctoral nursing students engaged in clinical training involving direct patient care\n2. Provision of electronic informed consent\n3. Access to the internet and a personal device (computer, tablet, or smartphone) for the asynchronous components of the blended teaching model\n4. No participation in a formal comprehensive pain management course within the previous 12 months\n\nExclusion Criteria:\n\n1. Inability to attend at least one face-to-face session or to complete online activities (e.g., due to repeated absences)\n2. Any self-reported or university-documented cognitive or mental health condition that prevented completion of questionnaires or participation in training\n3. Voluntary withdrawal at any stage of the study",true,"18 Years",{"count":52,"type":21},156,[24],"Pain management is a core competency in nursing practice, yet nursing students consistently demonstrate insufficient knowledge, unfavorable attitudes, limited competence, and low self-efficacy in this area. Artificial intelligence (AI)-based educational tools, particularly ChatGPT, have emerged as promising resources in nursing education; however, rigorous experimental evidence on their effectiveness remains scarce.\n\nThis study is a two-arm, parallel-group randomized controlled trial (RCT) that aims to evaluate the effect of a ChatGPT-driven blended teaching model for pain management on nursing students' knowledge and attitudes toward pain, nursing competence, and learning self-efficacy.\n\nEligible nursing students at Shahid Beheshti University of Medical Sciences (Tehran, Iran) will be randomly assigned in a 1:1 ratio to either:\n\n* Intervention group: ChatGPT-assisted blended clinical nursing rounds (8 sessions over 4 weeks, each 90 minutes, combining bedside rounds with AI-assisted pre- and post-round activities)\n* Control group: Traditional clinical nursing rounds (same number and duration of sessions, without any AI tools)\n\nOutcomes will be measured at baseline (1 week before intervention), immediate post-test (1 week after intervention), and 3-month follow-up using validated instruments: the Nurses' Knowledge and Attitudes Survey Regarding Pain (NKASRP), the Nursing Student Competence Scale (NSCS), and the Nursing Students' Learning Self-Efficacy instrument (NLSE).\n\nFindings will provide empirical evidence to guide educational policy and curriculum design in nursing programs, with the goal of improving pain management education and patient care outcomes.",[56,57,58],"Pain Management","Nursing Education","Knowledge, Attitudes, Practice",[60,61,62,56,63,64,65],"ChatGPT","Artificial Intelligence","Blended Learning","Nursing Students","Clinical Competence","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-04-20",{"date":69,"type":33},"2026-04-27",{"date":71,"type":21},"2026-09-01",{"date":73,"type":21},"2027-01-01",{"name":39,"class":40},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100626432","homogeneous-vs-heterogeneous-learning-style-grouping-in-problem-based-learning-among-nurses-100626432","NCT07435558","Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses","Effect of Homogeneous and Heterogeneous Grouping Based on the Felder-Silverman Learning Style Model on Problem-Based Learning Outcomes Among Nurses: A Parallel Randomized Clinical Trial","Inclusion Criteria:\n\n1. written informed consent;\n2. at least one year of clinical nursing experience;\n3. availability to attend all scheduled workshop sessions (no planned extended leave during the intervention period);\n4. completion of the Index of Learning Styles (ILS) questionnaire and availability of valid ILS scores for group allocation\n\nExclusion Criteria:\n\n1. attendance in a similar PBL or patient-safety educational program within the previous 6-12 months;\n2. significant uncorrectable hearing or vision impairment or severe cognitive\u002Fpsychiatric condition that precluded participation;\n3. concurrent participation in another interventional study likely to affect study outcomes;\n4. repeated non-attendance (\\>2 missed sessions) or voluntary withdrawal after randomization.",{"count":83,"type":21},78,[24],"Problem-based learning (PBL) is a learner-centered educational approach that helps nurses improve clinical skills through group discussion, case analysis, and collaborative problem-solving. However, the way participants are assigned to learning groups may influence how effectively they learn. Differences in learning styles among group members can affect participation, confidence, interaction quality, and knowledge retention.\n\nThe Felder-Silverman Learning Style Model (FSLSM) is a widely used framework that categorizes learners based on how they perceive, process, and understand information (e.g., active vs. reflective, visual vs. verbal). Organizing PBL groups according to similarities or differences in these learning styles may lead to different educational outcomes.\n\nThis study is a parallel, two-arm randomized controlled clinical trial designed to compare the effects of homogeneous grouping (participants with similar learning styles placed in the same group) versus heterogeneous grouping (participants with diverse learning styles placed in the same group) on PBL outcomes among hospital nurses.\n\nRegistered nurses employed in teaching hospitals affiliated with Shahid Beheshti University of Medical Sciences are randomly assigned to one of the two grouping strategies. All participants receive the same PBL curriculum focused on patient safety and medication safety. The only difference between groups is the method used to form discussion teams.\n\nThe primary outcome is medication safety competence, measured using a validated questionnaire. Secondary outcomes include clinical reasoning competence and nursing care quality. Outcomes are assessed at baseline, immediately after the intervention, and eight weeks later to evaluate both immediate effects and short-term retention.\n\nThe findings of this study are expected to clarify whether grouping nurses based on similar or diverse learning styles leads to better improvement and retention of critical clinical competencies. Results may help educators design more effective PBL programs in nursing education and clinical training settings.",[87,88,89],"Problem-based Learning in Nursing Education","Nurses","Randomized Clinical Trial","2026-02-26",{"date":92,"type":33},"2026-03-02",{"date":94,"type":21},"2026-03-07",{"date":96,"type":21},"2026-07-15",{"name":39,"class":40},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":41},"100563176","naringenin-supplementation-in-bone-fracture-patients-100563176","NCT06612762","Naringenin Supplementation in Bone Fracture Patients","Effect of Naringenin Supplementation on the Speed of Bone Fusion and the Concentration of Plasma Inflammatory Factors in Patients With Bone Fractures.","Inclusion Criteria:\n\n* Candidate for orthopedic surgery for bone fractures of the lower limbs,\n* Ambulatory without assistance for a minimum of two months prior to the fracture.\n* Not having undergone amputation of the lower limbs.\n* Not suffering from liver cirrhosis.\n* Not suffering from advanced kidney failure (blood creatinine higher than 1.4 mg\u002FdL).\n* Not having metastatic cancer, any chronic inflammatory diseases, nor taking any drugs that affect bone metabolism, including calcitonin, bisphosphonates, and corticosteroids.\n\nExclusion Criteria:\n\n* Allergy or intolerant reaction to narangenin capsules\n* Any abnormal changes in their liver, kidneys tests,\n* Failure to consume more than 10% of their capsules","60 Years",{"count":20,"type":21},[24],"Fractures of the lower extremities represent a significant proportion of injuries sustained by polytrauma patients, with a notable association with prolonged hospitalization, chronic disability, and impaired physical functioning. The occurrence of surgical site infections (SSI) represents a significant threat to the efficacy of osteosynthesis procedures. As with other traumas and surgical procedures, the secretion of inflammatory mediators is markedly elevated in this cohort of patients following surgery. Naringenin is one of the most prevalent flavonoids, occurring naturally in grapefruit and other citrus fruits. In vitro studies have demonstrated that naringenin may stimulate the release of osteogenic cytokines and suppress the production of pro-inflammatory factors, which can result in a reduction in bone resorption. Based on these findings, naringenin may prove an effective agent for accelerating the rate of fusion and controlling inflammation. Furthermore, it may enhance quality of life and augment functional activity.",[110],"Bone Fractures","2026-02-21",{"date":113,"type":33},"2026-02-24",{"date":115,"type":33},"2024-11-03",{"date":117,"type":21},"2026-06-01",{"name":39,"class":40},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":41},"100625485","phase-4-tirzepatide-spartina-in-obese-kidney-transplant-recipients-100625485","NCT07423247","Tirzepatide (Spartina) in Obese Kidney Transplant Recipients","Safety and Efficacy of Tirzepatide (Spartina) in Obese Kidney Transplant Recipients: A Pilot Study on Weight Loss, Gastrointestinal Tolerability, and Graft Function","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Kidney transplant recipient with ≥12 months since transplantation\n* BMI ≥ 27 kg\u002Fm²\n* Stable graft function in the last 3 months (serum creatinine variation \\\u003C 20%)\n* Stable immunosuppressive regimen\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* History of pancreatitis\n* Severe gastroparesis\n* History of medullary thyroid carcinoma (MTC) or MEN2 syndrome\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²\n* Acute rejection episode within the past 6 months\n* Any condition judged by the investigator to interfere with study participation or safety",{"count":127,"type":21},30,[129],"PHASE4","Post-transplant obesity is a common complication after kidney transplantation, largely attributed to recovery from uremia, increased appetite, sedentary lifestyle, and long-term corticosteroid exposure. Obesity in kidney transplant recipients increases the risk of cardiovascular disease, post-transplant diabetes mellitus (PTDM), and may contribute to graft injury through hyperfiltration-related mechanisms, potentially leading to reduced graft survival. Current approaches for weight management in transplant recipients, including lifestyle modification, are often insufficient, while bariatric surgery carries considerable risks and concerns regarding altered absorption of immunosuppressive medications.\n\nTirzepatide (Iranian brand name: Spartina), the first dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated superior effects on weight reduction and glycemic control compared with earlier GLP-1 receptor agonists in the general population. However, its use in kidney transplant recipients requires careful evaluation due to potential gastrointestinal adverse effects, dehydration risk, and possible interaction with calcineurin inhibitor absorption caused by delayed gastric emptying.\n\nThis prospective single-arm pilot clinical trial aims to assess the preliminary safety and efficacy of tirzepatide in obese kidney transplant recipients with stable graft function. Outcomes include changes in anthropometric indices, percent weight change, gastrointestinal tolerability, immunosuppressive drug trough levels, and graft function over 24 weeks of treatment.",[132],"Tirzepatide","2026-02-13",{"date":135,"type":33},"2026-02-20",{"date":137,"type":33},"2026-01-01",{"date":139,"type":21},"2026-09",{"name":39,"class":40},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100624350","impact-of-ai-based-research-training-on-nursing-students-100624350","NCT07408492","Impact of AI-Based Research Training on Nursing Students","The Impact of Artificial Intelligence-Powered Research Training Course on Nursing Students' Research Literacy, Attitude, and Readiness to Use Artificial Intelligence","Inclusion Criteria:\n\n1. Enrolled in a nursing program (bachelor's, master's, or doctoral level) at one of the participating universities during the study term.\n2. Completion of at least one course in research methodology in their program curriculum.\n3. Willingness to participate and to provide written informed consent.\n\nExclusion Criteria:\n\n1. Prior completion of advanced courses specifically on research-oriented AI or formal AI certification programs.\n2. Inability to attend the scheduled intervention sessions or to access the online learning platform.\n3. Not complete the study questionnaires at all required time points\n4. Withdrawal of consent or failure to complete baseline assessments.",{"count":149,"type":21},104,[24],"The goal of this clinical trial is to find out whether an artificial intelligence (AI)-powered research training course can improve nursing students' research skills, attitudes toward artificial intelligence, and readiness to use AI in research and education.\n\nThe main questions this study aims to answer are:\n\nDoes AI-powered research training improve nursing students' understanding of research methods?\n\nDoes this training improve nursing students' attitudes toward artificial intelligence?\n\nDoes the course increase nursing students' readiness and confidence to use artificial intelligence in research-related activities?\n\nResearchers will compare nursing students who take an AI-powered research training course with students who receive usual education without AI-based training.\n\nParticipants will:\n\nBe randomly assigned to either the AI-powered research training group or the usual education group\n\nComplete online questionnaires about research skills, attitudes toward artificial intelligence, and readiness to use AI\n\nAttend assessments at three time points: before the course, immediately after the course, and three months later\n\nThe AI-powered research training course includes structured sessions on research methods and the responsible use of artificial intelligence tools for literature review, research design, data analysis support, and academic writing. The results of this study may help improve research education and support the safe and effective use of artificial intelligence in nursing education and research.",[153,57,154],"Research Awareness","Artificial Intelligence (AI)","2026-02-11",{"date":133,"type":33},{"date":158,"type":21},"2026-03-01",{"date":160,"type":21},"2026-07-01",{"name":39,"class":40},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100593380","using-mscs-for-chronic-active-antibody-mediated-rejection-100593380","NCT07005687","Using MSCs for Chronic Active Antibody Mediated Rejection","Inclusion Criteria:\n\n* chronic active antibody mediated rejection in kidney transplanted recipients\n\nExclusion Criteria:\n\n\\-",{"count":169,"type":21},10,[24],"Mesenchymal stem cell (MSCs) therapy has already been studied in kidney transplant recipients (KTRs), and the available data showed that it is safe and well tolerated. The aim of this study was to evaluate the safety and efficacy of autologous MSCs in combination with standard therapy in KTRs with biopsy-proven chronic active antibody-mediated rejection (AMR). Patients with biopsy-proven chronic active AMR received treatment with autologous bone marrow-derived MSCs (3 × 106 cells\u002Fkg iv) after completion of standard therapy and were followed for up to 12 months. The primary endpoints were safety by assessment of adverse events. Secondary endpoints included assessment of kidney graft function, immunological and histological changes related to AMR activity and chronicity assessed by conventional microscopy and molecular transcripts. A total of 3 patients were enrolled in the study before it was terminated prematurely because of adverse events. We found that AMR did not improve in any of the patients after treatment with MSCs. In addition, serious adverse events were observed in one case when autologous MSCs therapy was administered in the late phase after kidney transplantation, which requires further elucidation.",[173],"Kidney Transplant Rejection","2026-02-08",{"date":155,"type":33},{"date":177,"type":21},"2027-12-01",{"date":179,"type":21},"2029-07-01",{"name":39,"class":40},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":41},"100593445","treatment-of-chronic-active-antibody-mediated-rejection-with-tocilizumab-100593445","NCT07006532","Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab","Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients With Tocilizumab ,IVIG, Plasmapheresis, Rituximab Versus IVIG, Plasmapheresis , Rituximab","Inclusion Criteria:\n\n1. Signed written informed consent\n2. eGFR\\> 25 cc\u002Fmin\n3. Chronicity index \\\u003C8\n4. IFTA\\\u003C40%\n5. EBV IgG positive\n\nExclusion Criteria:\n\n1. Active or recurrent infections\n2. History of malignancy, unless in remission for more than 2 years with no relapse\n3. abnormal liver function tests\n4. Platelet \\\u003C 100,000",{"count":189,"type":21},50,[24],"Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR). Annually, 5000 kidney transplants are lost in the United States due to CAMR. The two-year graft survival rate in CAMR is approximately 20%, highlighting the need for a more efficient therapy for CAMR and directly targeting donor specific antibody (DSA) producing cells and reducing CAMRThere is no established treatment for this problem. While many centers intensify and optimize the dosage of immunosuppressive drugs, treatments such as plasmapheresis, IVIG, and rituximab, although effective in treating AMR, have not been successful in reducing DSA or improving kidney graft survival in CAMR patients. Despite these treatments, two-year graft survival can increase up to 55%. The use of anti-plasma cell treatments like bortezomib has also yielded inconsistent results.",[173],{"date":155,"type":33},{"date":195,"type":33},"2025-01-01",{"date":197,"type":21},"2027-05-01",{"name":39,"class":40},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":215,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":4},"100615362","synchrony-optimized-non-invasive-ventilation-education-program-and-icu-patients-100615362","NCT07291622","Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients","Effect of a Synchrony-Optimized Non-Invasive Ventilation Education Program on Intensive Care Unit Patients' Outcomes: A Randomized Clinical Trial Protocol","Inclusion Criteria:\n\n* Adult patients over 18 years of age\n* Admitted to the ICU for at least 24 hours\n* Anticipated to be hospitalized for more than one week\n* Receiving NIV treatment for any underlying condition\n* Capable of learning\n* Proficient in the Persian language\n\nExclusion Criteria:\n\n* Patients with Richmond Agitation-Sedation Scale (RASS) scores of +4 or -5\n* Patients with cognitive disorders\n* Patients with neurological disorders\n* Patients with anxiety disorders\n* Patients whose condition deteriorates, making continued cooperation impossible\n* Patients unable to participate in educational sessions",{"count":207,"type":21},92,[24],"The aim of this clinical trial is to find out whether a synchrony-optimized education program for non-invasive ventilation (NIV) can help ICU patients use their ventilator more effectively and improve their comfort, symptoms, and psychological well-being.\n\nResearchers want to answer these main questions:\n\nCan a structured two-session NIV education program help patients use their ventilator more regularly and for longer periods?\n\nDoes this type of training reduce anxiety, depression, and respiratory symptoms?\n\nCan synchrony training improve patients' comfort and reduce NIV-related problems such as mask leaks or sleep disturbances?\n\nIs this program more effective than the routine ICU education normally provided?\n\nWhat Will Happen in the Study\n\nAdults (18+) who are receiving NIV in the ICU will participate in this study.\n\nParticipants will be randomly assigned to one of two groups:\n\nIntervention Group: Will receive the SYNC-NIV education program, consisting of:\n\nOne hands-on session (20-40 minutes) teaching patients how to synchronize their breathing with the ventilator\n\nOne supplementary session (45-60 minutes) covering mask management, preventing complications, reducing leaks, breathing exercises, equipment care, and alarm handling\n\nAn educational booklet for continued support\n\nControl Group: Will receive the standard ICU education normally provided about the ICU environment, general care, communication, and monitoring.\n\nAll participants will be evaluated at three times:\n\nbefore the intervention, the day after the program ends, and one week later.",[211,212,213,214],"Ventilator Associated Events","Asynchrony, Patient-Ventilator","Intensive Care (ICU)","Noninvasive Ventilation",[216,217,218,219,89,220],"Non-Invasive Ventilation","Patient-Ventilator Synchrony","Intensive Care Unit (ICU)","Anxiety and Depression","Patient Comfort","2025-12-17",{"date":223,"type":33},"2025-12-24",{"date":225,"type":21},"2025-12-19",{"date":227,"type":21},"2026-01-10",{"name":39,"class":40},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":132,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":41},"100606523","efficacy-and-safety-of-tirzepatide-spartina-in-chronic-kidney-failure-100606523","NCT07176663","Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure","Safety and Effectiveness of Tirzepatide(Spartina )in Chronic Kidney Failure a Single-center Study","Inclusion Criteria:\n\nage ≥18 years and history of diabetes or BMI over 27\n\nExclusion Criteria:\n\nPrevious usage of similar therapy for less than 3 months owing to the inability to capture all efficacy and safety endpoints within this brief timeframe and\u002For nonadherence to tirzepatide therapy",{"count":237,"type":21},15,[24],"Diabetes management presents a complex clinical scenario marked by several challenges, especially in chronic kidney failure. These include navigating potential drug interactions between oral antidiabetic therapies and other agents. Furthermore, these patients may experience various adverse drug effects, such as lactic acidosis, electrolyte abnormalities such as hypomagnesemia, fluid retention, and lipid derangements, which can further augment overall morbidity. Consequently, many patients receive insulin. However, prolonged intensive insulin therapy may be linked to several adverse outcomes, including an increased risk of hypoglycemia and weight gain.\n\nHence, a common practice is to transition to medications commonly used other populations of patients. With their established benefits on glycemic control, cardiovascular health, renal benefits, and weight management, in conjunction with the aforementioned adverse effects associated with other oral antidiabetics agents, glucagon-like peptide-1 receptor agonists have emerged as an attractive therapeutic option for patients with kidney failure.",[241],"Obesity","2025-12-06",{"date":244,"type":33},"2025-12-15",{"date":246,"type":21},"2026-02-01",{"date":248,"type":21},"2026-05-01",{"name":39,"class":40},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":41},"100600898","interactive-binocular-treatment-i--bit-in-adult-patients-with-anisometropic-amblyopia-100600898","NCT07103473","Interactive Binocular Treatment (I- BiT) in Adult Patients With Anisometropic Amblyopia","1. Age range from 18 to 40 years\n2. Best corrected visual acuity of 0.3 log units or worse in one eye\n3. Cases of mild and moderate anisometropic amblyopia (BCVA≤0.3)","40 Years",{"count":237,"type":21},[24],"Amblyopia is one of the common, preventable and treatable causes of decreased acuity of one or both eyes without a specific organic cause. Common treatments include optical correction, patching (closing the healthy eye), perceptual learning, and drug treatments. The patient's low cooperation, reduction in effectiveness and long treatment period of common methods have led to the design of new treatments that eliminate these disadvantages, among which binocular vision treatments can be mentioned. The purpose of this study is to apply a new and innovative method under binocular conditions in the treatment of anisometropic amblyopia in adults. In this randomized clinical trial study, 30 people (15 patients in the case group and 15 patients in the control group) aged 18 to 40 years with amblyopia (decrease in best corrected vision worse than 0.3 logarithmic units in one of the eyes or the difference of the corrected minimum visual acuity of two lines between two eyes) in the form of two groups of 15 people (case and control) will be included in the study. Patients will be randomly divided into two groups: case and control. Interactive Binocular Treatment (I-BiT) is used in the case group and usual games without I-BiT system are used as placebo in the other group. For this purpose, the games will be presented in the control group in such a way that the two eyes will not be dissociated and the patient will see all the targets in the same way with his two eyes. I-BiT is a new method for the treatment of amblyopia in which a person plays age-appropriate games using special glasses in a 3D space. The stimuli are shown differently to the two eyes and both eyes are involved in the treatment process. The selection of people in two groups will be such that background variables such as age, sex, as well as the severity of amblyopia or vision loss in the two groups are the same and confounding factors are under control. First, all eye examinations such as measuring visual acuity, lateral vision, checking refractive errors with and without cycloplegic drops, checking the alignment of visual axes, and also checking the anterior and posterior segments of the eye are performed. After the definitive diagnosis of amblyopia, people in both groups will be asked to use the given virtual games in the same way for one month, 5 sessions per week, each session for 30 minutes. In order to control the amount of use of computer games by patients, the duration of time that people use games will be controlled and recorded online using software by design engineers. Patients will be examined before treatment, one month after treatment and also one month after stopping treatment.",[261],"Amblyopia","2025-08-04",{"date":264,"type":33},"2025-08-05",{"date":266,"type":21},"2025-12-10",{"date":268,"type":21},"2025-12-29",{"name":39,"class":40},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":289,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100600579","interactive-vs-standard-video-education-for-improving-outcomes-in-hemodialysis-patients-100600579","NCT07099326","Interactive vs. Standard Video Education for Improving Outcomes in Hemodialysis Patients","Examining the Effects of Interactive Versus Conventional Video-Based Education on Activation, Treatment Adherence, and Weight Changes in Dialysis Patients: A Randomized Clinical Trial Protocol","Inclusion Criteria:\n\n1. Willingness to participate in the study;\n2. Literate (ability to read and write);\n3. Alertness and orientation to time, place, and person sufficient to respond to questions;\n4. No history of hearing or visual impairments;\n5. No cognitive disorders;\n6. Possession of a personal mobile phone or any other device capable of running interactive videos, and the ability to use it;\n7. No use of psychoactive medications;\n8. Confirmed diagnosis of chronic kidney disease by a nephrology specialist and having a medical record in the dialysis unit;\n9. Age between 18 and 65 years.\n\nExclusion Criteria:\n\n1. Withdrawal from the study at any stage;\n2. Failure to receive and watch the provided videos;\n3. Patient death;\n4. Transfer to a healthcare center outside the coverage of Shahid Beheshti University of Medical Sciences.","65 Years",{"count":279,"type":21},165,[24],"The goal of this clinical trial is to find out if educational videos-especially interactive ones-can help people on dialysis better manage their treatment.\n\nResearchers want to answer the following main questions:\n\nCan interactive or conventional video-based education help patients better understand and follow their treatment plan? Does this type of education improve patients' ability to control their weight changes between dialysis sessions? Does this type of education improve patients' activation? Is interactive video education more effective than regular (non-interactive) video education?\n\nWhat Will Happen in the Study:\n\nAdults on hemodialysis will take part in the study.\n\nThey will be randomly assigned to one of three groups:\n\nGroup A: Will receive 10 interactive educational video sessions (30 minutes each).\n\nGroup B: Will receive the same videos but in a non-interactive format. Group C (Control Group): Will receive routine education normally given at the dialysis center.\n\nVideos will be watched on a web platform. Interactive videos include pop-up questions and scenario-based feedback.\n\nAll participants will be followed up immediately, 1 month, and 3 months after the program ends.\n\nWhat Participants Will Do:\n\nWatch educational videos over several days (totaling 5 hours).\n\nAnswer questions and engage in follow-up group discussions.\n\nComplete surveys about their knowledge, treatment adherence, and health behaviors.\n\nGet weighed before and after dialysis sessions to monitor fluid retention.\n\nThis study aims to improve how dialysis patients manage their condition and to help healthcare providers design better educational tools.",[283,284,285,286,287,288],"Hemodialysis","Nurse","Educational Videos","Patient Activation","Weight Change","Treatment Adherence",[290,291,286,292,293,294],"Interactive Video-Based Education","Conventional Video-Based Education","Patient Treatment Adherence","Patients' Weight Changes","Dialysis","2025-07-31",{"date":264,"type":33},{"date":264,"type":21},{"date":299,"type":21},"2025-10-05",{"name":39,"class":40},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":319,"locationsCount":41},"100595546","evaluaion-the-short-term-effects-of-advograf-plus-rapamiune-after-kidney-transplantation-100595546","NCT07033858","Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation","Investigating the Effect of Low-dose Extended-release Tacrolimus and Sirolimus on the Short-term Outcomes of Allograft Kidney Transplantation","Inclusion Criteria:\n\n* All Kidney transplant recipients\n\nExclusion Criteria:\n\n* Kidney-Pancreas transplant BMI\\>30 cPRA\\>0%",{"count":189,"type":21},[24],"Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®\u002FAstagraf XL®, Astellas company).",[312],"Kidney Transplant; Complications","2025-06-14",{"date":315,"type":33},"2025-06-24",{"date":317,"type":33},"2025-03-01",{"date":160,"type":21},{"name":39,"class":40},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":49,"sex":16,"minAge":327,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":41},"100564581","phase-1-cell-therapy-with-anti-cd19-car-nk-cells-in-patients-with-relapsed-or-resistant-b-all-100564581","NCT06631040","Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL","Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-Acute Lymphocytic Leukemia","Inclusion Criteria:\n\nEligible diseases: Acute lymphocytic leukemia (ALL CD19+). Patients 3 years of age or older, and must have a life expectancy \\> 12 weeks. Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky performance status (KPS) score is higher than 60.\n\nFemales of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of CAR NK cells.\n\nAdequate bone marrow, liver and renal function as assessed by the following laboratory requirements: White blood cell count (WBC) ≥ 2500c\u002Fml, Platelets ≥ 50×10\\^9\u002FL, Hb ≥ 9.0g\u002FdL, lymphocyte (LY) ≥ 0.7×10\\^9\u002FL, LY% ≥ 15%, Alb ≥ 2.8g\u002FdL, serum lipase and amylase \\\u003C 1.5×upper limit of normal, serum creatinine ≤ 2.5mg\u002FdL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg\u002FdL. These tests must be conducted within 7 days prior to registration.\n\nAbility to give informed consent.\n\nExclusion Criteria:\n\nPregnant or nursing women may not participate. Active HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at the time of screening.\n\nSerious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive\u002Frestrictive pulmonary disease, or psychiatric or emotional disorders.\n\nHistory of severe immediate hypersensitivity to any of the agents including cyclophosphamide, fludarabine, or aldesleukin.\n\nConcurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.\n\nThe existence of unstable or active ulcers or gastrointestinal bleeding. Patients need anticoagulant therapy (such as warfarin or heparin). Patients need long-term antiplatelet therapy (aspirin at a dose \\> 300mg\u002Fd; clopidogrel at a dose \\> 75mg\u002Fd).\n\nPatients using fludarabine or cladribine chemotherapy within 3 months prior to leukapheresis.","3 Years",{"count":169,"type":21},[330,331],"PHASE1","PHASE2","Immunotherapy has shown promise in treating hematological malignancies, including resistant B-ALL. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific cancer antigens. While CAR-NK therapy offers advantages over CAR-T therapy, such as reduced immune system reactions and lower production time and cost, challenges remain regarding antitumor efficacy and the tumor microenvironment. Preclinical and early clinical studies have targeted various antigens, including CD19, with CAR-NK cells in resistant B-ALL. To further investigate the potential of anti-CD19 CAR-NK cell therapy, this study aims to evaluate its safety and determine the maximum tolerated dose (MTD) in patients who have not responded to standard treatment.",[334],"Acute Lymphocytic Leukemia in Relapse",[336,337],"CAR-NK Therapy","anti-CD19","2024-10-06",{"date":340,"type":33},"2024-10-08",{"date":342,"type":21},"2024-12-19",{"date":344,"type":21},"2026-12-30",{"name":39,"class":40},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":277,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":4},"100562944","effectiveness-of-thyme-in-the-management-of-clinical-symptoms-in-patients-with-irritable-bowel-syndrome-100562944","NCT06609746","Effectiveness of Thyme in the Management of Clinical Symptoms in Patients with Irritable Bowel Syndrome","The Effect of Low FODMAP (Fermentable, Oligo-, Di-, Mono-saccharides and Polyols) Diet with Thyme on Clinical Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome","Inclusion Criteria:\n\n* Ages 18-65;\n* Patients with irritable bowel syndrome;\n* Body Mass Index in the range of 18-25 kg\u002Fm2\n\nExclusion Criteria:\n\n* Any organic intestinal disease;\n* Medical history of chronic gastrointestinal and colorectal disease;\n* Any major bowel surgery;\n* Medical history of liver and kidney disorders;\n* Regular use of laxative, anti-diarrhea and anti inflammatory medications.",{"count":354,"type":21},52,[24],"The goal of this clinical trial is to learn if thyme supplement enhances the effects of a low FODAMP diet on reducing clinical symptoms and improving the quality of life of patients with irritable bowel syndrome or not.\n\nThe main questions it aims to answer are:\n\n1. Does consumption of thyme reduce the severity score of clinical symptoms in patients with irritable bowel syndrome?\n2. Does consumption of thyme increase the quality of life score in patients with irritable bowel syndrome? Researchers will compare thyme supplementation with placebo to see if thyme supplement enhances the effects of a low FODAMP diet on clinical symptoms and quality of life in patients with irritable bowel syndrome.\n\nParticipants will:\n\n1. Receive thyme supplement plus a low FODMAP diet or placebo with low FODMAP diet for 8 weeks.\n2. Recorde 3 days (1weekend and 2 workday) dietary recalls at week 4 and week 8 to assess adherence to the low FODMP diet.\n3. Visit the clinic at the beginning of the study and the end of the study for a check-up and score record",[358],"Irritable Bowel Syndrome (IBS)","2024-09-21",{"date":361,"type":33},"2024-09-24",{"date":363,"type":21},"2024-10-21",{"date":365,"type":21},"2025-04",{"name":39,"class":40},{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":41},"100534701","phase-1-anti-bcma-car-nk-therapy-in-relapsed-or-refractory-multiple-myeloma-100534701","NCT06242249","Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma","Determining Safety and Maximum Tolerated Dose (MTD) of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma","Inclusion Criteria:\n\n1. Age 18-80 years with expected survival \\> 3 months.\n2. Confirmed diagnosis of active multiple myeloma with detectable BCMA expression in malignant cells.\n3. Relapsed or refractory disease with at least 2 prior lines of treatment, including a proteasome inhibitor and immunomodulator, without achieving significant efficacy.\n4. Measurable disease at screening according to IMWG criteria, as defined by any of the following: Serum monoclonal paraprotein (M-protein) level ≥1.0 g\u002FdL or urine M-protein level being as defined； or light chain MM without measurable disease in the serum or the urine； serum immunoglobulin free light chain disease dL and abnormal serum immunoglobulin kappa\u002Flambda free light chain ratio\n5. ECOG performance status of 0-1.\n6. Acceptable cardiac, liver, and kidney function.\n7. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Uncontrolled active infection, HIV infection, or positive syphilis serology reaction.\n3. Active hepatitis B or hepatitis C infection.\n4. Recent or current use of glucocorticoids or other immunosuppressors.\n5. Severe cardiac, liver, renal insufficiency, diabetes, or other diseases.\n6. Participation in other clinical research in the past three months.","80 Years",{"count":169,"type":21},[330,331],"Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific cancer antigens. While CAR-NK therapy offers advantages over CAR-T therapy, such as reduced immune system reactions and lower production time and cost, challenges remain in terms of antitumor efficacy and the tumor microenvironment. Preclinical and early clinical studies have targeted various antigens, including BCMA, with CAR-NK cells in multiple myeloma. To further investigate the potential of BCMA-targeted CAR-NK cell therapy, this study aims to evaluate its safety and determine the maximum tolerated dose (MTD) in patients who have not responded to standard therapy.",[379],"Multiple Myeloma, Refractory",[336,381],"Anti-BCMA","2024-03-03",{"date":384,"type":33},"2024-03-06",{"date":386,"type":21},"2024-04-30",{"date":388,"type":21},"2026-06-30",{"name":39,"class":40},""]